Turbo Cancer Treatment Race Is On: Johnson & Johnson Just Completed $2 Billion Cancer Drug Buy of Ambrx

295 0

Merck, Novartis, Sanofi, Eli Lilly, AbbVie, Pfizer, BMS – they all want in!

Articles reviewed:

11, 2024 – Pfizer bets on cancer drugs to recover from rapid decline of covid business
11, 2024 – Merck Completes Acquisition of Harpoon Therapeutics
7, 2024 – Johnson & Johnson Completes Acquisition of Ambrx ($2.0 billion)
12, 2024 – AbbVie Completes $10.1 billion Acquisition of ImmunoGen
5, 2024 – Novartis in the lead to acquire cancer drug developer MorphoSys-sources
26, 2023 – Bristol Myers Squibb announces intent to buy RayzeBio for $4.1 billion (104% premium)
22, 2023 – Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
8, 2023 – Bristol Myers Squibb announces purchase of Mirati Therapeutics for $5.8 billion
3, 2023 – Eli Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

Mar. 11, 2024 – Pfizer bets on cancer drugs to recover from rapid decline of covid business

Pfizer’s $43 billion acquisition of Seagen doubled Pfizer’s cancer drug pipeline to 60 different experimental programs
Pfizer had a 4 hour investor event recently
Chris Boshoff, a longtime Pfizer executive who leads Pfizer’s oncology research and development, said during the investor event that Pfizer has 10 manufacturing sites producing cancer drugs on three continents, while Seagen had just one.
Pfizer expects 2/3 of its oncology revenue to come from new drugs and new indications for existing products by end of decade.
The “outdo cancer” catchphrase caught on during Pfizer’s 60–second Super Bowl ad that it reportedly spent more than $14 million on — which boasted the big pharma company’s 175-history as “Don’t Stop Me Now.”
Pfizer said it can produce 8 blockbuster cancer drugs by 2030

Mar. 11, 2024 – Merck Completes $650 million Acquisition of Harpoon Therapeutics

“We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, president, Merck Research Laboratories.
Harpoon has a number of cancer drugs in the pipeline called “T-cell engagers” for small cell lung cancer, neuroendocrine tumors, multiple myeloma, etc.
The acquisition is part of Merck’s focus on cancer and exploration of immuno-oncology. In fact, Merck said it has one of the industry’s largest development programs, spanning 30-plus tumor types. The biopharmaceutical giant added it continues to strengthen its portfolio through purchases, as with Harpoon.
Merck announced several deals in 2023, including the up to $610 million acquisition of biopharmaceutical company Caraway Therapeutics and its $10.8 billion purchase of Prometheus Bioscienes Inc.
“Using its proprietary Tri-specific T cell Activating Construct (TriTAC) platform, the engineered proteins tell a patient’s own T-cells to attack target cells that express specific proteins, or antigens, carried by the target cells. To that end, Harpoon’s ProTriTAC platform keeps the T-cell engager inactive until it reaches the tumor.”

Mar. 7, 2024 – Johnson & Johnson Completes Acquisition of Ambrx ($2.0 billion)

“Johnson & Johnson (NYSE: JNJ) announced it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion”
“The acquisition presents a distinct opportunity for Johnson & Johnson to design, develop and commercialize targeted oncology therapeutics”
“The Ambrx team has developed a promising pipeline and ADC platform that will be a strong complement and strategic fit to our oncology innovation strategy”
“Ambrx’s proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side effects typically associated with chemotherapy”

Feb. 12, 2024 – AbbVie Completes $10.1 billion Acquisition of ImmunoGen (95% premium)

AbbVie has completed a $10.1 billion acquisition of cancer drug maker ImmunoGen.
“Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with cancer,” said Robert A. Michael, president and chief operating officer, AbbVie. “The addition of ImmunoGen’s treatment for ovarian cancer will accelerate our ability to help patients today, expand our oncology pipeline and drive long-term revenue growth well into the next decade.”
“ImmunoGen’s follow-on pipeline of ADCs further builds on AbbVie’s existing solid tumor pipeline of novel targeted therapies and next-generation immuno-oncology assets, which have the potential to create new treatment possibilities across multiple solid tumors and hematologic malignancies”

Feb. 5, 2024 – Novartis in the lead to acquire cancer drug developer MorphoSys ($1.6 billion Euros)

Novartis is in advanced talks to acquire MorphoSys AG (MORG.DE), a German developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion)
MorphoSys main revenue generator is a lymphoma drug called Monjuvi
Monjuvi’s U.S. net product sales were $92 million in 2023, and that it expected these sales to come in between $80 million and $95 million in 2024. The company has said it expects revenue to go up as Monjuvi is approved for more indications.
Headquartered in Planegg, Germany, MorphoSys develops drugs to fight deadly forms of cancers such as myelofibrosis, which is a rare type of bone marrow cancer, and certain types of lymphomas.
Ultimately, the acquisition is not entirely driven by the portfolio, and Novartis is seeking to use its previous collaborative experience with MorphoSys to expand its developments internally

Dec. 26, 2023 – Bristol Myers Squibb announces intent to buy RayzeBio for $4.1 billion (104% premium)

The company’s RayzeBio acquisition bolsters the company’s longer-term effort to establish a presence in the buzzing radiopharma scene. By spending $62.50 per share to buy RayzeBio, BMS adds a pipeline of actinium-based radiopharmaceutical therapeutics (RPTs) to its fold.
“…….include potential treatments for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small cell lung cancer and hepatocellular carcinoma, among other cancers.”
Actinium-based radiopharmaceutical therapeutics (RPTs) work by binding to tumor cells and killing the cancer cells through targeted radiation
“Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors—delivering radioactive payloads to cancer cells in a targeted manner,” BMS’ chief medical officer, Samit Hirawat, M.D., said in a statement.
From RayzeBio’s perspective, the biotech believes Bristol’s “well-established presence in oncology and deep expertise in developing, commercializing and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution”
Major competitors in the radiopharma arena include Novartis and its established lutetium-based medicines Lutathera and Pluvicto, plus new entrant Eli Lilly after it forked over $1.4 billion for Point Biopharma Global.

Nov. 22, 2023 – Boehringer Ingelheim expands immuno-oncology portfolio with the (450 million CHF) acquisition of bacterial cancer therapy specialist T3 Pharma

“Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15-20% of cancer patients. Boehringer Ingelheim aims to considerably increase this rate by utilizing complementary immuno-oncology platforms such as T-Cell Engagers (TcEs), oncolytic viruses, and cancer vaccines, which have the potential to turn cold tumors into hot ones, extending the benefits of immunotherapy to more patients”
“The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs. This will bring us closer to achieving our vision of driving a paradigm shift in cancer care treatments”
“T3 Pharma has developed a unique platform using engineered Yersinia enterocolitica bacteria to deliver bioactive proteins directly and selectively into the tumor micro-environment, while sparing healthy tissues. The bacteria can be loaded with multiple immune-modulatory proteins of choice, enabling the design of immuno-oncology combination therapies in one single agent.”
“This strategy aims to enable smart combinations that deliver life-changing and best-in-class treatments that may offer the greatest benefit for people affected by cancer.”

Oct. 8, 2023 – Bristol Myers Squibb announces purchase of Mirati Therapeutics for $5.8 billion

S. health regulator had in December approved Mirati’s lung cancer drug, Krazati, to treat adults with advanced lung cancer.
The oral drug — the company’s only approved product — is designed to target a mutated form of a gene known as KRAS, which occurs in about 13% of non-small cell lung cancer
In early October, Bristol Myers Squibb moved on Mirati after a yearslong courtship, inking a buyout worth up to $5.8 billion for the cancer specialist and its FDA-approved lung cancer drug Krazati.

Oct. 3, 2023 – Eli Lilly to Acquire POINT Biopharma (for $1.4 billion) to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

Eli Lilly announced a definitive agreement to acquire POINT Biopharma, radiopharmaceutical company with a pipeline of radioligand therapies in development for the treatment of cancer.
“POINT operates a 180,000-square-foot radiopharmaceutical manufacturing campus in Indianapolis, as well as a radiopharmaceutical research and development center in Toronto”
“POINT aims to transform precision oncology by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177”
“We are excited by the potential of this emerging modality and see the acquisition of POINT as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers”
“Over the past few years, we have seen how well-designed radiopharmaceuticals can demonstrate meaningful results for patients with cancer and rapidly integrate into standards of care, yet the field remains in the early days of the impact it may ultimately deliver,” said Jacob Van Naarden, President of Loxo@Lilly, the oncology unit of Eli Lilly and Company
“POINT’s lead programs are in late-phase development. PNT2002 is a prostate-specific membrane antigen (PSMA) targeted radioligand therapy in development for patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on hormonal treatment”

My Take

Pfizer spent $43 billion to acquire Seagen (42% premium).

Johnson & Johnson spent $2 billion to buy Ambrx.

AbbVie spent $10.1 billion to buy Immunogen at 95% premium.

Bristol Myers Squibb to buy Mirati Therapeutics for $5.8 billion at 52% premium.

Bristol Myers Squibb to buy RayzeBio for $4.1 billion at 104% premium.

Novartis in the lead to acquire cancer drug developer MorphoSys ($1.6 billion Euros).

Eli Lilly is spending $1.4 billion to acquire Point Biopharma Global and according to Forbes, is paying a 90% premium.

Boehringer spent 450 million CHF to buy T3 Pharma and its targeted bacteria platform.

Conclusion

While the covid mRNA vaccine injured who develop turbo cancers are being gaslit by low level doctors and MD propagandists on Twitter and other virtual communication networks, Big Pharma is in a literal feeding frenzy, buying up every “novel” cancer treatment imaginable at massive premiums.

When my cancer treatment program was illegally sabotaged by Alberta Health Services starting in 2016, and AHS seriously harmed or outright murdered over 2450 of my cancer patients at Cross Cancer Institute in Edmonton, which led to a $13.5 million lawsuit against AHS which is still ongoing, there was no money in the cancer treatments I was providing (targeted radiopharmaceuticals).

In 2023, two of these acquisitions involve my Cancer Treatments & Expertise: Bristol Myers Squibb $4.1 billion deal for RayzeBio and Eli Lilly’s $1.4 billion deal for Point Biopharma Global.

Trudeau re-built my Cancer Program in Vancouver, British Columbia as “ARTMS” which was just acquired by Telix for $82 million on Mar.4, 2024 – how much investment Trudeau and his Liberal friends have in that (would make great investigative journalism for anyone interested).

Bottom line is, whether establishment doctors believe in mRNA Induced turbo cancer or not is irrelevant, hundreds of billions will be made treating it.

In 2023, the top 10 Big Pharma buyout deals came to $115.8 billion, increasing from 2022 ($65 billion) and 2021 ($53 billion).

Author: Dr. William Makis, Canadian physician with expertise in Radiology, Oncology and Immunology. Governor General’s Medal, University of Toronto Scholar. Author of 100+ peer-reviewed medical publications.

yogaesoteric
March 27, 2024